Literature DB >> 25178730

Dyslipidaemia: cardiovascular prevention--end of the road for niacin?

Sony Tuteja1, Daniel J Rader2.   

Abstract

The recently published HPS2–THRIVE study has shown that the addition of extended release niacin to statin therapy in patients with well-controlled levels of LDL cholesterol does not reduce the risk of cardiovascular events and might even increase harm. Consequently, the use of niacin to increase levels of HDL cholesterol is not recommended.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25178730     DOI： 10.1038/nrendo.2014.159

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  10 in total

1.  The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?

Authors:  Daniel J Rader; Alan R Tall
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

2.  Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice.

Authors:  Jun Yoshino; Kathryn F Mills; Myeong Jin Yoon; Shin-ichiro Imai
Journal:  Cell Metab       Date:  2011-10-05       Impact factor: 27.287

3.  Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.

Authors:  Martina Lukasova; Camille Malaval; Andreas Gille; Jukka Kero; Stefan Offermanns
Journal:  J Clin Invest       Date:  2011-02-07       Impact factor: 14.808

4.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

5.  CRTH2 is a critical regulator of neutrophil migration and resistance to polymicrobial sepsis.

Authors:  Makoto Ishii; Koichiro Asano; Ho Namkoong; Sadatomo Tasaka; Kosuke Mizoguchi; Takahiro Asami; Hirofumi Kamata; Yoshifumi Kimizuka; Hiroshi Fujiwara; Yohei Funatsu; Shizuko Kagawa; Jun Miyata; Ken Ishii; Masataka Nakamura; Hiroyuki Hirai; Kinya Nagata; Steven L Kunkel; Naoki Hasegawa; Tomoko Betsuyaku
Journal:  J Immunol       Date:  2012-04-27       Impact factor: 5.422

6.  Major lipids, apolipoproteins, and risk of vascular disease.

Authors:  Emanuele Di Angelantonio; Nadeem Sarwar; Philip Perry; Stephen Kaptoge; Kausik K Ray; Alexander Thompson; Angela M Wood; Sarah Lewington; Naveed Sattar; Chris J Packard; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-11-11       Impact factor: 56.272

7.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

Authors:  P L Canner; K G Berge; N K Wenger; J Stamler; L Friedman; R J Prineas; W Friedewald
Journal:  J Am Coll Cardiol       Date:  1986-12       Impact factor: 24.094

8.  Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Authors:  S Matthijs Boekholdt; Benoit J Arsenault; G Kees Hovingh; Samia Mora; Terje R Pedersen; John C Larosa; K M A Welch; Pierre Amarenco; David A Demicco; Andrew M Tonkin; David R Sullivan; Adrienne Kirby; Helen M Colhoun; Graham A Hitman; D John Betteridge; Paul N Durrington; Michael B Clearfield; John R Downs; Antonio M Gotto; Paul M Ridker; John J P Kastelein
Journal:  Circulation       Date:  2013-08-21       Impact factor: 29.690

9.  Effects of extended-release niacin with laropiprant in high-risk patients.

Authors:  Martin J Landray; Richard Haynes; Jemma C Hopewell; Sarah Parish; Theingi Aung; Joseph Tomson; Karl Wallendszus; Martin Craig; Lixin Jiang; Rory Collins; Jane Armitage
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

Review 10.  Residual macrovascular risk in 2013: what have we learned?

Authors:  Jean-Charles Fruchart; Jean Davignon; Michel P Hermans; Khalid Al-Rubeaan; Pierre Amarenco; Gerd Assmann; Philip Barter; John Betteridge; Eric Bruckert; Ada Cuevas; Michel Farnier; Ele Ferrannini; Paola Fioretto; Jacques Genest; Henry N Ginsberg; Antonio M Gotto; Dayi Hu; Takashi Kadowaki; Tatsuhiko Kodama; Michel Krempf; Yuji Matsuzawa; Jesús Millán Núñez-Cortés; Carlos Calvo Monfil; Hisao Ogawa; Jorge Plutzky; Daniel J Rader; Shaukat Sadikot; Raul D Santos; Evgeny Shlyakhto; Piyamitr Sritara; Rody Sy; Alan Tall; Chee Eng Tan; Lale Tokgözoğlu; Peter P Toth; Paul Valensi; Christoph Wanner; Alberto Zambon; Junren Zhu; Paul Zimmet
Journal:  Cardiovasc Diabetol       Date:  2014-01-24       Impact factor: 9.951
  10 in total
  3 in total

Review 1.  Current therapies for lowering lipoprotein (a).

Authors:  Julian C van Capelleveen; Fleur M van der Valk; Erik S G Stroes
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

2.  Metabolism of PLTP, CETP, and LCAT on multiple HDL sizes using the Orbitrap Fusion Lumos.

Authors:  Sasha A Singh; Allison B Andraski; Hideyuki Higashi; Lang Ho Lee; Ashisha Ramsaroop; Frank M Sacks; Masanori Aikawa
Journal:  JCI Insight       Date:  2021-02-08

Review 3.  Multi-omics: Opportunities for research on mechanism of type 2 diabetes mellitus.

Authors:  Shuai Wang; Hui Yong; Xiao-Dong He
Journal:  World J Diabetes       Date:  2021-07-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.